Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | Her2-receptor negative breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | Her2-receptor negative breast cancer | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 12% (3/25) and stable disease in 16% (4/25) of patients with CD274 (PD-L1)-positive (combined positive score >=1) advanced ER-positive, ERBB2 (HER2)-negative breast cancer, with a median duration of response of 12.0 months (PMID: 29559561; NCT02054806). | 29559561 |
PubMed Id | Reference Title | Details |
---|---|---|
(29559561) | Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. | Full reference... |